---

---

entities : Novartis ag    symbols : Incy   

save search

---

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -4.76% | O: -0.23% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -5.42% | O: -0.07% H: 0.09% C: -0.7%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -19.39% | O: -0.66% H: 4.19% C: 3.13%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| -1.05% | O: 0.22% H: 0.22% C: -0.93%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -11.76% | O: 0.03% H: 1.47% C: -0.72%
year update financial results

---

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| -1.6% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 12.87% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | $9.47 -1.11% 520K |

Manufacturing

| -12.2% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -7.48% | O: 0.14% H: 0.35% C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -6.14% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -5.55% | O: 0.7% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -3.21% | O: 1.22% H: 0.07% C: -0.43%
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| -1.49% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -1.65% | O: -0.18% H: 0.48% C: -1.91%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| -3.85% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | $14.08 -0.99% -0.99% 470K |

Health Technology

| -22.73% | O: -1.15% H: 1.03% C: -1.5%
VRTX | News | $394.43 0.24% 0.24% 1.3M |

Health Technology

| -5.79% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| 0.22% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K |

Health Technology

| -5.43% | O: -3.1% H: 1.2% C: -0.8%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -9.49% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -20.58% | O: -3.72% H: 0.58% C: -3.82%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 11.63% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $360.11 0.47% 0.47% 330K |

Health Technology

| -8.27% | O: -2.3% H: 1.65% C: 0.83%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -8.66% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

---

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -3.0% | O: 1.03% H: 0.73% C: 0.58%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 0.11% | O: -1.09% H: 1.03% C: 0.91%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| 5.21% | O: 1.32% H: 0.45% C: -1.19%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 121.43% | O: 2.22% H: 0.6% C: -9.4%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -3.72% | O: -0.28% H: 1.0% C: -0.46%
presentation meeting

---

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -9.89% | O: -0.11% H: 0.72% C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M |

Health Technology

| -21.28% | O: 6.91% H: 1.49% C: -2.49%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -21.35% | O: 0.03% H: 0.17% C: -1.19%
BNTX | $86.82 0.75% 0.75% 1.6M |

Health Technology

| -19.94% | O: 4.23% H: 0.0% C: -4.4%
ADAP | $0.97 7.97% 7.38% 1.5M |

Health Technology

| -30.0% | O: 1.43% H: 2.11% C: -1.41%
companies report cancer pancreatic global

---

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-14 (Crawled : 01:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 37.45% | O: -0.18% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 15.62% | O: 0.28% H: 0.38% C: 0.31%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -35.3% | O: 1.2% H: 0.17% C: -1.67%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 359.85% | O: -1.79% H: 3.39% C: 3.39%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -28.46% | O: 0.18% H: 1.06% C: 0.94%
meeting

---

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 35.82% | O: 2.27% H: 0.0% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -16.2% | O: -0.13% H: 1.01% C: 0.89%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 10.4% | O: 0.29% H: 0.86% C: 0.72%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -49.81% | O: -0.19% H: 1.15% C: -2.27%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 258.88% | O: 1.6% H: 0.0% C: -0.59%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -37.94% | O: -1.02% H: 0.29% C: -3.04%
financial

---

Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 43.49% | O: 1.13% H: 0.0% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| 0.15% | O: 0.68% H: 1.05% C: -0.23%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 16.31% | O: 0.47% H: 0.09% C: -0.55%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -34.36% | O: 1.07% H: 2.51% C: -0.11%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 271.49% | O: 3.1% H: 1.8% C: -0.6%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -29.58% | O: 1.59% H: 7.26% C: 1.89%
financial results

---

Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-08-02 (Crawled : 12:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 25.2% | O: -2.62% H: 0.0% C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -7.54% | O: -1.33% H: 0.78% C: -1.06%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 10.2% | O: -0.02% H: 0.39% C: -0.64%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -34.38% | O: -0.32% H: 5.09% C: 3.9%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 218.79% | O: -3.37% H: 3.3% C: 0.92%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -32.36% | O: -4.39% H: 0.2% C: -1.92%
results

---

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
Published: 2022-05-26 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -11.29% | O: -0.17% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 3.26% | O: -0.11% H: 0.0% C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -18.78% | O: -0.33% H: 0.0% C: 0.0%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 249.13% | O: 3.5% H: 2.14% C: 0.19%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -31.05% | O: 1.26% H: 0.95% C: -1.13%

---

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 7.86% | O: -0.39% H: 0.15% C: -1.07%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -32.53% | O: 3.73% H: 0.09% C: -3.98%
jakavi treatment disease approval

---

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 7.83% | O: 0.06% H: 0.0% C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -27.81% | O: 2.08% H: 1.96% C: -0.77%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 239.25% | O: 2.45% H: 0.92% C: -2.03%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -29.77% | O: 2.12% H: 4.06% C: 1.39%
results

---

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 9.77% | O: 1.14% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -33.05% | O: 0.33% H: 0.29% C: 0.01%
jakavi treatment disease positive chmp

---

Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-23 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| -1.85% | O: 3.81% H: 0.0% C: -0.44%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 6.47% | O: -4.55% H: 6.28% C: 6.28%
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -51.99% | O: -1.94% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 9.89% | O: -0.6% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -8.52% | O: -0.87% H: 0.0% C: 0.0%
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -31.25% | O: -0.55% H: 0.0% C: 0.0%
MGNX | $15.62 -2.8% -2.88% 1M |

Health Technology

| 70.79% | O: -1.31% H: 3.88% C: -0.67%
KURA | $17.55 -0.74% -0.74% 1.3M |

Health Technology

| 6.96% | O: -1.34% H: 0.12% C: -2.6%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -32.93% | O: 0.04% H: 0.08% C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 7.88% | O: -0.31% H: 1.85% C: 1.55%
ADXS | $0.57 12.48% 9.5K |

Health Technology

| 367.21% | O: -1.64% H: 8.33% C: 0.0%
CVM | $1.56 4.0% 0.0% 230K |

Health Technology

| -64.22% | O: -0.92% H: 2.31% C: -3.47%
report cancer market

---

New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Published: 2021-11-04 (Crawled : 15:15) - globenewswire.com
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 11.81% | O: 0.18% H: 0.0% C: -0.89%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 12.88% | O: -0.06% H: 0.28% C: 0.18%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -18.96% | O: 2.41% H: 0.0% C: 0.0%
ema car-t platform

---

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-11-02 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -6.43% | O: 0.49% H: 0.56% C: -0.07%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 12.55% | O: 0.3% H: 0.15% C: -0.4%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -53.91% | O: 2.7% H: 1.01% C: 0.85%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 51.67% | O: 3.75% H: 1.22% C: 1.22%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -21.67% | O: -1.93% H: 0.19% C: -3.14%
financial results results

---

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 13.62% | O: 0.17% H: 0.08% C: -0.47%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -31.17% | O: -3.87% H: 1.0% C: -4.83%
disease treatment fda fda approval approval

---

Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -20.91% | O: -0.06% H: 0.0% C: -0.6%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 2.27% | O: 0.3% H: 0.17% C: 0.17%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -40.46% | O: 0.55% H: 1.32% C: 1.03%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| 28.7% | O: -2.43% H: 0.88% C: 0.44%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -33.29% | O: -0.7% H: 0.31% C: 0.04%
financial results results

---

Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 5.23% | O: 0.84% H: 0.01% C: -0.81%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -38.49% | O: 0.9% H: 0.49% C: -1.25%
disease fda

---

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Published: 2021-05-19 (Crawled : 22:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 7.64% | O: -0.46% H: 1.21% C: 0.78%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -35.93% | O: 0.12% H: 3.3% C: 2.08%
cancer breast cancer

---

Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M |

Health Technology

| -21.38% | O: -0.12% H: 0.0% C: -1.25%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 9.23% | O: -0.82% H: 0.28% C: -0.06%
XNCR | $18.385 -2.98% -3.07% 830K |

Health Technology

| -57.79% | O: -0.96% H: 0.0% C: -5.61%
MOR | News | $17.96 -0.5% -0.5% 180K |

Health Technology

| -24.36% | O: -4.71% H: 0.33% C: -2.65%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -38.79% | O: -2.37% H: 2.04% C: -2.95%
financial results results

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---